Results 21 to 30 of about 863,756 (239)

Immunomodulation by imiquimod in patients with high-risk primary melanoma. [PDF]

open access: yes, 2012
Imiquimod is a synthetic Toll-like receptor 7 (TLR7) agonist approved for the topical treatment of actinic keratoses, superficial basal cell carcinoma, and genital warts.
Antoni Ribas   +48 more
core   +2 more sources

Etiology of Severe Non-malaria Febrile Illness in Northern Tanzania: A Prospective Cohort Study. [PDF]

open access: yes, 2013
The syndrome of fever is a commonly presenting complaint among persons seeking healthcare in low-resource areas, yet the public health community has not approached fever in a comprehensive manner.
AJ Bouley   +52 more
core   +6 more sources

The serlogical specificity of the lectin from Lens culinaris [PDF]

open access: yes, 1973
Lens culinaris, the common lentil, contains a lectin which has been shown to be specific for a glycoprotein saliva antigen and a glycolipoprotein serum antigen.
Heritage, Deborah Ward
core   +1 more source

Leveraging current insights on IL‐10‐producing dendritic cells for developing effective immunotherapeutic approaches

open access: yesFEBS Letters, EarlyView.
In vivo IL‐10 produced by tissue‐resident tolDC is involved in maintaining/inducing tolerance. Depending on the agent used for ex vivo tolDC generation, cells acquire common features but prime T cells towards anergy, FOXP3+ Tregs, or Tr1 cells according to the levels of IL‐10 produced. Ex vivo‐induced tolDC were administered to patients to re‐establish/
Konstantina Morali   +3 more
wiley   +1 more source

Blood group typing in five Afghan populations in the North Hindu-Kush region: implications for blood transfusion practice.

open access: yes, 2013
International audienceBACKGROUND AND OBJECTIVES: Blood incompatibility arises from individual and ethnic differences in red blood cell (RBC) antigen profiles. This underlines the importance of documenting RBC antigen variability in various ethnic groups.
Chiaroni, J.   +5 more
core   +3 more sources

The potential role of T-cells and their interaction with antigen-presenting cells in mediating immunosuppression following trauma-hemorrhage [PDF]

open access: yes, 2009
Objective: Trauma-hemorrhage results in depressed immune responses of antigen-presenting cells (APCs) and T-cells. Recent studies suggest a key role of depressed T-cell derived interferon (IFN)-g in this complex immune cell interaction.
Abraham E.   +15 more
core   +1 more source

FoxO1 signaling in B cell malignancies and its therapeutic targeting

open access: yesFEBS Letters, EarlyView.
FoxO1 has context‐specific tumor suppressor or oncogenic character in myeloid and B cell malignancies. This includes tumor‐promoting properties such as stemness maintenance and DNA damage tolerance in acute leukemias, or regulation of cell proliferation and survival, or migration in mature B cell malignancies.
Krystof Hlavac   +3 more
wiley   +1 more source

Blood types [PDF]

open access: yes, 2011
Krv je specifična tjelesna tekućina koja se sastoji od krvnih stanica i krvne plazme. Krvna grupa je klasificirana na temelju prisutnosti ili odsutnosti naslijeđenih antigena koji se nalaze na površini crvenih krvnih stanica.
Brižić, Matea
core   +2 more sources

Cloning and expression of porcine β1,4 N-acetylgalactosaminyl transferase encoding a new xenoreactive antigen [PDF]

open access: yes, 2014
Xenograft rejection of pigs organs with an engineered mutation in the GGTA-1 gene (GTKO) remains a predominantly antibody mediated process which is directed to a variety of non-Gal protein and carbohydrate antigens.
Byrne, GW   +4 more
core   +2 more sources

Insights into PI3K/AKT signaling in B cell development and chronic lymphocytic leukemia

open access: yesFEBS Letters, EarlyView.
This Review explores how the phosphoinositide 3‐kinase and protein kinase B pathway shapes B cell development and drives chronic lymphocytic leukemia, a common blood cancer. It examines how signaling levels affect disease progression, addresses treatment challenges, and introduces novel experimental strategies to improve therapies and patient outcomes.
Maike Buchner
wiley   +1 more source

Home - About - Disclaimer - Privacy